The importance of EGFR mutation testing in squamous cell carcinoma or non-small cell carcinoma favor squamous cell carcinoma diagnosed from small lung biopsies

Table 3 Results from current studies of EGFR-TKI efficacy on ADSC

Study	No. of patients	Ethnicity	Stage		Gender		Smoking status		EGFR activating mutation		Type of TKI	DCR (%)	PFS (m)	OS (m)
Study	No. of patients	Ethnicity	I-IIIA	≥ IIIB	Male	Female	No	Yes	Positive	Negative	Type of TKI	DCR (%)	PFS (m)	OS (m)
Song et al., 2013 [17]	49	Asia	N/A		53.1% (26/49)	46.9% (23/49)	26.5% (13/49)	73.4% (36/49)	33.30% (7/21)	66.7% (14/21)	Gefitinib/ Erotinib	65.3% (32/49)	4.3 (2.1 for EGFR-; 8.7 for EGFR+)	17.6
Fan et al., 2017 [30]	27	Asia	85.2% (23/27)	14.8% (4/27)	40.7% (11/27)	59.3% (16/27)	74.1% (20/27)	25.9% (7/27)	100% (27/27)	0% (0/27)	N/A	74.1% (20/27)	15	39
Zhang et al., 2018 [28]	148	Asia	100% (148/148)	0% (0/148)	70.7% (102/148)	29.3% (46/148)	42.6% (63/148)	57.4% (85/148)	20.2% (30/148)	79.8% (118/148)	Gefitinib/ Erotinib	76.7% (23/30)	N/A	43

DCR Disease control rate, PFS Progression free survival, OS Overall survival, N/A Not applicable, TKI Tyrosine kinase inhibitor, EGFR- EGFR activating mutation negative, EGFR+ EGFR activating mutation positive

ISSN: 1746-1596